Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-Glc + Api (also known as AD-Glc/Api) is a preclinical click-chemistry-based albumin nanocomplex developed as a theranostic platform for the treatment and imaging of idiopathic pulmonary fibrosis (IPF). The nanocomplex is synthesized by functionalizing native albumin with dibenzocyclooctyne (DBCO) to form AD, followed by the conjugation of azide-glucose via strain-promoted azide–alkyne cycloaddition (SPAAC) to yield glucose-functionalized albumin (AD-Glc). The active flavonoid apigenin (Api) is then loaded onto the AD-Glc carrier. The glucose ligand targets fibrotic lung tissue and inflammatory M1 macrophages by exploiting their upregulated glucose metabolism via glucose transporter 1 (GLUT1). Apigenin acts as the active therapeutic payload, exerting antifibrotic, anti-inflammatory, and antioxidant effects by scavenging reactive oxygen species (ROS) and inhibiting transforming growth factor-beta (TGF-β) signaling. In preclinical models of bleomycin-induced pulmonary fibrosis, AD-Glc/Api has demonstrated the ability to reduce inflammation, suppress epithelial-mesenchymal transition (EMT), inhibit fibroblast activation, and decrease collagen deposition, while also enabling non-invasive PET imaging tracking when radiolabeled.
| Indication | Highest phase | Status |
|---|---|---|
| idiopathic pulmonary fibrosis (IPF) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AD-Glc + Api.
Work on AD-Glc + Api? Claim this page to correct or add information. Claim this page